**KSMO 2023** In-Person & Virtual
Korean Society of Medical Oncology

SEP 7 (THU) - 8 (FRI), 2023
SEOUL, KOREA

16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

*Please provide your CV of 1-2 pages in length including details of the following items. This will be posted on the conference website.

• **Full Name: Hye Seung Lee**

• **Current Position & Affiliation: Professor, Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine**

• **Country: Republic of Korea**

---

• **Educational Background:**

| | |
|---|---|
| 1991 - 1997 | M.D., Seoul National University College of Medicine |
| 1998 - 2000 | M.S., Medicine (Pathology), Graduate School of Seoul National University |
| 2000 - 2002 | Ph.D., Medicine (Pathology), Graduate School of Seoul National University |

• **Professional Experience:**

| | |
|---|---|
| 2005 – 2012 | Clinical Assistant Professor, Seoul National University Bundang Hospital |
| 2008 – 2009 | Guest Researcher, National Institute of Health/ National Cancer Institute/ Molecular Oncology Branch, MD, U.S.A |
| 2012 – 2017 | Clinical Associate Professor, Seoul National University Bundang Hospital |
| 2017 – 2020 | Endowed Professor, Seoul National University Bundang Hospital, Seoul National University College of Medicine |
| 2020 – now | Professor, Seoul National University Hospital, Seoul National University College of Medicine |

• **Professional Organizations:**

| | |
|---|---|
| 2016 – now | Cancer Research and Treatment, Associate Editor |
| 2020 – 2024 | The Korean Cancer Association, Director of Publication Committee |
| 2021 – 2022 | The Korean Society of Pathologists, Director of Quality Assurance/Control |
| 2023 – 2024 | The Korean Society of Pathologists, Secretary General |

• **Main Scientific Publications:**

Kwon HJ, Park Y, Nam SK, Kang E, Kim KK, Jeong I, Kwak Y, Yoon J, Kim TY, Lee KW, Oh DY, Im SA, Kong SH, Park DJ, Lee HJ, Kim HH, Yang HK, Lee HS. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment. Cancer Med. 2023 May;12(9):10371-10384.

Park Y, Nam SK, Seo SH, Park KU, Oh HJ, Park YS, Suh YS, Ahn SH, Park DJ, Kim HH, Lee HS. Comprehensive Study of Microsatellite Instability Testing and Its Comparison With Immunohistochemistry in Gastric Cancers. J Gastric Cancer. 2023 Apr;23(2):264-274.

Park YS, Kook MC, Kim BH, Lee HS, Kang DW, Gu MJ, Shin OR, Choi Y, Lee W, Kim H, Song IH, Kim KM, Kim HS, Kang G, Park DY, Jin SY, Kim JM, Choi YJ, Chang HK, Ahn S, Chang MS, Han SH, Kwak Y, Seo AN, Cho MY. A standardized pathology report for gastric cancer: 2nd edition. J Pathol Transl Med. 2023 Jan;57(1):1-27.

Vijayakurup V, Maeng K, Lee HS, Meyer B, Burkett S, Nawab A, Dougherty MW, Jobin C, Mahmud I, Garrett TJ, Feely M, Lee KB, Kaye FJ, Guijarro MV, Zajac-Kaye M. Thymidylate synthase accelerates Men1-mediated pancreatic tumor progression and reduces survival. JCI Insight. 2022 Oct 10;7(19):e147417.

Na HY, Park Y, Nam SK, Koh J, Kwak Y, Ahn SH, Park DJ, Kim HH, Lee KS, Lee HS. Prognostic significance of natural killer cell-associated markers in gastric cancer: quantitative analysis using multiplex immunohistochemistry. J Transl Med. 2021 Dec 24;19(1):529.

KSMO 2023 In-Person & Virtual Korean Society of Medical Oncology
SEP 7 (THU) - 8 (FRI), 2023
SEOUL, KOREA

16th Annual Meeting of the Korean Society of Medical Oncology & 2023 International Conference · 11th International FACO Conference

Park Y, Seo AN, Koh J, Nam SK, Kwak Y, Ahn SH, Park DJ, Kim HH, Lee HS. Expression of the immune checkpoint receptors PD-1, LAG3, and TIM3 in the immune context of stage II and III gastric cancer by using single and chromogenic multiplex immunohistochemistry. Oncoimmunology. 2021 Jul 25;10(1):1954761.

Yun S, Koh J, Nam SK, Kwak Y, Ahn SH, Do Park J, Kim HH, Kim WH, Lee HS. Immunoscore is a strong predictor of survival in the prognosis of stage II/III gastric cancer patients following 5-FU-based adjuvant chemotherapy. Cancer Immunol Immunother. 2021 Feb;70(2):431-441.

Koh J, Nam SK, Kwak Y, Kim G, Kim KK, Lee BC, Ahn SH, Park DJ, Kim HH, Park KU, Kim WH, Lee HS. Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas. J Pathol. 2021 Jan;253(1):94-105.

Park Y, Koh J, Na HY, Kwak Y, Lee KW, Ahn SH, Park DJ, Kim HH, Lee HS. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs. Cancer Res Treat. 2020 Jul;52(3):661-670.

Kwak Y, Koh J, Park Y, Hong YJ, Park KU, Kim HH, Park DJ, Ahn SH, Kim WH, Lee HS. Differential prognostic impact of CD8+ T cells based on human leucocyte antigen I and PD-L1 expression in microsatellite-unstable gastric cancer. Br J Cancer. 2020 Apr;122(9):1399-1408.

Kim B, Nam SK, Seo SH, Park KU, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS. Comparative analysis of HER2 copy number between plasma and tissue samples in gastric cancer using droplet digital PCR. Sci Rep. 2020 Mar 6;10(1):4177.

Koh J, Lee KW, Nam SK, Seo AN, Kim JW, Kim JW, Park DJ, Kim HH, Kim WH, Lee HS. Development and Validation of an Easy-to-Implement, Practical Algorithm for the Identification of Molecular Subtypes of Gastric Cancer: Prognostic and Therapeutic Implications. Oncologist. 2019 Dec 11;24(12):e1321-e1330.

Koh J, Nam SK, Lee YW, Kim JW, Lee KW, Ock CY, Oh DY, Ahn SH, Kim HH, Kang KW, Kim WH, Lee HY, Lee HS. Trastuzumab Specific Epitope Evaluation as a Predictive and Prognostic Biomarker in Gastric Cancer Patients. Biomolecules. 2019 Nov 26;9(12).

Park Y, Koh J, Kwak Y, Ahn SH, Park DJ, Kim HH, Kim WH, Lee HS. Clinicopathologic significance of human leukocyte antigen class I expression in patients with stage II and III gastric cancer. Cancer Immunol Immunother. 2019 Nov;68(11):1779-1790.